Showing results (481-490 of 700) with videos related to
Sort By:
Pageof 70
Journal of Diabetes and Its Complications|November 25, 2025
Efficacy and safety of finerenone in Asian patients with type 2 diabetes and chronic kidney disease: A FIDELITY analysis by baseline kidney functionShigehiro Katayama, Stefan D Anker, Dalong Zhu, et al.Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|August 31, 2020
The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristicsDavid C Wheeler, Bergur V Stefansson, Mikhail Batiushin, et al.Nephron|January 11, 2023
Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes and Chronic Kidney DiseaseTherese Adrian, Mads Hornum, Filip Krag Knop, et al.Journal of the American College of Cardiology|May 20, 2021
Finerenone Reduces New-Onset Atrial Fibrillation in Patients With Chronic Kidney Disease and Type 2 DiabetesGerasimos Filippatos, George L Bakris, Bertram Pitt, et al.Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy|June 24, 2024
New Diabetic Treatment by Alleviation of Autonomic Nervous System Dysfunction Measured as Periosteal Pressure Sensitivity at Sternum Improves Empowerment, Treatment Satisfaction, and Self-Reported Health of People with Type 2 Diabetes: A Randomized TrialSofie Korsgaard Hecquet, Søren Ballegaard, Ebbe Eldrup, et al.The New England Journal of Medicine|November 6, 2012
Cardiorenal end points in a trial of aliskiren for type 2 diabetesHans-Henrik Parving, Barry M Brenner, John J V McMurray, et al.Cardiovascular Diabetology|July 19, 2022
Circulating metabolites and molecular lipid species are associated with future cardiovascular morbidity and mortality in type 1 diabetesLuis F Ferreira-Divino, Tommi Suvitaival, Viktor Rotbain Curovic, et al.Diabetic Medicine : a Journal of the British Diabetic Association|June 20, 2026
Extracellular matrix proteins as risk markers for complications in type 1 diabetesMarte Opseth Rygg, Alexandra Louise Møller, Viktor Rotbain Curovic, et al.Diabetes, Obesity & Metabolism|December 9, 2022
Reduction of cardiac adipose tissue volume with short-term empagliflozin treatment in patients with type 2 diabetes: A substudy from the SIMPLE randomized clinical trialNiels H Brandt-Jacobsen, Mikkel Jürgens, Philip Hasbak, et al.Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|February 8, 2020
Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trialHiddo J L Heerspink, Bergur V Stefansson, Glenn M Chertow, et al.Pageof 70